52620 Long-term safety and efficacy of secukinumab over 236 weeks in children and adolescents with severe chronic plaque psoriasis: Results of a double-blind, randomized controlled phase III trial

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2024
This article has no abstract
Epistemonikos ID: 9168853d05250327da9919b5e5b3e61236ebc329
First added on: Feb 18, 2025